Adocia SA (LON: 0QAI)

Market Cap	77.41M
Revenue (ttm)	3.05M
Net Income (ttm)	-17.56M
Shares Out	n/a
EPS (ttm)	-1.28
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,958
Average Volume	2,048
Open	6.20
Previous Close	6.51
Day's Range	6.02 - 6.22
52-Week Range	4.30 - 10.07
Beta	0.97
RSI	42.61
Earnings Date	Apr 17, 2025

About Adocia

Adocia SA, a clinical-stage biotechnology company, researches and develops formulations of pre-approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. Its proprietary BioChaperone technological platform provides molecular delivery of therapeutic proteins. The company’s clinical product pipeline includes insulin formulations, such as BioChaperone Lispro U100 and U200, which are ultra-rapid formulations based on rapid insulin lispro; BioChaperone Combo, a combination of acting insulin glargine and ra...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2005
• Employees: 78
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0QAI

Financial Performance

In 2023, Adocia's revenue was 6.05 million, a decrease of -65.16% compared to the previous year's 17.36 million. Losses were -21.16 million, 206.7% more than in 2022.

Financial numbers in EUR